Hana Pharm Co., Ltd. (293480.KS)
KRW 10850.0
(-0.73%)
KRW 10850.0
(-0.73%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 348.38 Billion KRW | 0.7% |
| 2022 | 345.96 Billion KRW | 13.99% |
| 2021 | 303.49 Billion KRW | 9.73% |
| 2020 | 276.57 Billion KRW | 5.15% |
| 2019 | 263.03 Billion KRW | 8.52% |
| 2018 | 242.37 Billion KRW | 71.23% |
| 2017 | 141.55 Billion KRW | 23.53% |
| 2016 | 114.59 Billion KRW | 24.21% |
| 2015 | 92.25 Billion KRW | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 353.89 Billion KRW | -1.17% |
| 2024 Q1 | 358.07 Billion KRW | 2.78% |
| 2023 Q2 | 344.34 Billion KRW | 0.57% |
| 2023 Q1 | 342.4 Billion KRW | -1.03% |
| 2023 FY | 348.38 Billion KRW | 0.7% |
| 2023 Q4 | 348.38 Billion KRW | 0.07% |
| 2023 Q3 | 348.13 Billion KRW | 1.1% |
| 2022 Q1 | 335.47 Billion KRW | 10.54% |
| 2022 FY | 345.96 Billion KRW | 13.99% |
| 2022 Q4 | 345.96 Billion KRW | 2.53% |
| 2022 Q3 | 337.42 Billion KRW | 2.26% |
| 2022 Q2 | 329.98 Billion KRW | -1.64% |
| 2021 Q3 | 284.85 Billion KRW | 1.02% |
| 2021 Q4 | 303.49 Billion KRW | 6.55% |
| 2021 FY | 303.49 Billion KRW | 9.73% |
| 2021 Q1 | 282.17 Billion KRW | 2.02% |
| 2021 Q2 | 281.96 Billion KRW | -0.07% |
| 2020 Q3 | 275.54 Billion KRW | 3.22% |
| 2020 Q4 | 276.57 Billion KRW | 0.37% |
| 2020 FY | 276.57 Billion KRW | 5.15% |
| 2020 Q1 | 270.5 Billion KRW | 2.84% |
| 2020 Q2 | 266.95 Billion KRW | -1.31% |
| 2019 Q4 | 263.03 Billion KRW | -0.5% |
| 2019 FY | 263.03 Billion KRW | 8.52% |
| 2019 Q3 | 264.34 Billion KRW | 1.04% |
| 2019 Q1 | 252.88 Billion KRW | 4.34% |
| 2019 Q2 | 261.62 Billion KRW | 3.45% |
| 2018 FY | 242.37 Billion KRW | 71.23% |
| 2018 Q3 | 251.47 Billion KRW | 77.12% |
| 2018 Q4 | 242.37 Billion KRW | -3.62% |
| 2018 Q2 | 141.98 Billion KRW | 0.0% |
| 2017 FY | 141.55 Billion KRW | 23.53% |
| 2016 FY | 114.59 Billion KRW | 24.21% |
| 2015 FY | 92.25 Billion KRW | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -75.763% |
| Dong-A Socio Holdings Co., Ltd. | 1957.1 Billion KRW | 82.199% |
| Ildong Holdings Co., Ltd. | 876.99 Billion KRW | 60.275% |
| HANDOK Inc. | 790.33 Billion KRW | 55.919% |
| Kukje Pharma Co., Ltd. | 170.61 Billion KRW | -104.188% |
| Yuhan Corporation | 2814.07 Billion KRW | 87.62% |
| Dong-A ST Co., Ltd. | 1315.21 Billion KRW | 73.511% |
| SAMSUNG PHARM. Co., LTD. | 93.47 Billion KRW | -272.689% |
| Hanmi Pharm. Co., Ltd. | 1952.03 Billion KRW | 82.153% |
| Hanall Biopharma Co.,Ltd | 239.74 Billion KRW | -45.314% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | 25.702% |
| Dong Sung Bio Pharm.Co.,Ltd. | 114.97 Billion KRW | -203.015% |
| MYUNGMOON Pharm co.,Ltd | 236.54 Billion KRW | -47.279% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -75.763% |
| Ilsung Pharmaceuticals Co., Ltd. | 419.18 Billion KRW | 16.891% |
| REYON Pharmaceutical Co., Ltd. | 499.77 Billion KRW | 30.291% |
| Aprogen pharmaceuticals,Inc. | 589.39 Billion KRW | 40.891% |
| JW Holdings Corporation | 1176.26 Billion KRW | 70.382% |
| Ildong Pharmaceutical Co., Ltd. | 611.26 Billion KRW | 43.005% |
| Chong Kun Dang Pharmaceutical Corp. | 1402.42 Billion KRW | 75.158% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 45.99% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | 0.485% |
| Hyundai Pharmaceutical Co., Ltd. | 154.04 Billion KRW | -126.165% |
| Samil Pharmaceutical Co.,Ltd | 370.68 Billion KRW | 6.014% |
| Jeil Pharmaceutical Co.,Ltd | 487.32 Billion KRW | 28.511% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -75.763% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1078.06 Billion KRW | 67.684% |
| Daewoong pharmaceutical Co.,Ltd | 1770.31 Billion KRW | 80.321% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 45.99% |
| Yuhan Corporation | 2814.07 Billion KRW | 87.62% |
| Jeil Pharma Holdings Inc | 879.99 Billion KRW | 60.411% |
| Yungjin Pharm. Co., Ltd. | 226.6 Billion KRW | -53.744% |
| Suheung Co., Ltd. | 993.73 Billion KRW | 64.942% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 45.99% |
| Samjin Pharmaceuticals Co., Ltd. | 419.9 Billion KRW | 17.031% |
| Korea United Pharm Inc. | 468.86 Billion KRW | 25.695% |
| CKD Bio Corp. | 293.78 Billion KRW | -18.585% |
| Daewon Pharmaceutical Co., Ltd. | 507.99 Billion KRW | 31.42% |
| Dongwha Pharm.Co.,Ltd | 564.97 Billion KRW | 38.336% |
| Whan In Pharm Co.,Ltd. | 401.22 Billion KRW | 13.17% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | 0.485% |
| Chong Kun Dang Holdings Corp. | 1456 Billion KRW | 76.072% |
| Boryung Corporation | 922.36 Billion KRW | 62.229% |
| Bukwang Pharmaceutical Co., Ltd. | 442.46 Billion KRW | 21.262% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | 25.702% |
| JW Lifescience Corporation | 255.83 Billion KRW | -36.175% |